RxDoctor Payments Data

Howard Sherman, MD

Cardiovascular Disease · Biddeford, MENPI 1225094592

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 1 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Every reported general payment came from a single manufacturer, Johnson & Johnson. That places this record below the midpoint for cardiovascular disease clinicians in ME, where the typical reported total is $169.

$25in general payments, 2019–2025

Across 1 payment — averaging $24.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$25
$447,694in research payments, 2019–2025

Across 57 payments — averaging $7854.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$362K
  • Kowa Research Institute, Inc.$79K
  • Janssen Research & Development, LLC$5K
  • Novartis$2K

What the payments were for

  • Food & beverage$25100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson1$25

How this compares

$25 in reported general payments places this provider in the 15th percentile of 99 cardiovascular disease providers in Maine.

See all cardiovascular disease providers in Maine

Medicare billing

Part B allowed, 2024
$96,159
Medicare patients
1,839
Services billed
3,148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban819$1,123,157
XareltoRivaroxaban295$390,178
JardianceEmpagliflozin118$161,660
EntrestoSacubitril/Valsartan67$105,745
Repatha SureclickEvolocumab18$25,068
Bumetanide316$17,161
Metoprolol Succinate1,035$15,032
BrilintaTicagrelor11$11,560
Atorvastatin Calcium874$8,371
Potassium Chloride216$6,197
NexletolBempedoic Acid11$6,118
Rosuvastatin Calcium243$5,204
Ezetimibe150$4,385
Metoprolol Tartrate504$3,155
Diltiazem 24hr Er (Cd)Diltiazem Hcl97$3,124

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$25$390,178295 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 99 cardiovascular disease providers in Maine.

Other cardiovascular disease in Biddeford

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →